Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
News|Videos|August 17, 2025

Diagnostic Imaging's Weekly Scan: August 11 — August 17 (Video Version)

Author(s)Jeff Hall

Catch up on the latest news, research and insights in radiology with our Weekly Scan.

Welcome to Diagnostic Imaging’s Weekly Scan, which offers an opportunity to catch up on the most well-viewed radiology content of the past week.

Earlier this week, the Journal of Nuclear Medicine published research revealed that having PSMA PET/CT scans before salvage radiotherapy resulted in higher rates of survival and biomechanical recurrence-free survival at one, three and five years.

In an interview with Diagnostic Imaging, neuroradiologist Tammie Benzinger discussed the utility of low-field MRI in facilitating appropriate triage and health equity for patients with suspected Alzheimer’s disease.

In a new digital breast tomosynthesis (DBT) study published in the European Journal of Radiology, researchers found a 78 percent malignancy rate when DBT images showed a combination of architectural distortion with highly suspicious masses or microcalcifications.

In the second part of a Reading Room Podcast on emerging trends in theranostics for prostate cancer, Jeremie Calais, M.D., Ph.D., discussed the potential of alpha-emitting therapies. Here is a clip from the podcast.

Earlier this week, the FDA granted 510(k) clearance for the NeedleVue LC1 ultrasound system. While traditional ultrasound guidance for interventional procedures can be thwarted by complex calibration and reduced sensitivity, the multidirectional design with the NeedleVue LC1 Ultrasound System reportedly allows high-fidelity tracking from a variety of orientations.

Watch the video summary below of Diagnostic Imaging’s Weekly Scan.


Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Radiology and Building the Alzheimer’s Care Pathway of the Future
Given the increasing prevalence of Alzheimer’s disease and a staggering number of people with dementia who are undiagnosed, this author discusses five essential keys for radiologists and their colleagues to facilitate earlier detection, precision care treatment and monitoring to help ensure timely care and intervention.